CUDC-305 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This CUDC-305 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 4 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether CUDC-305 can convert its Not disclosed profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | CUDC-305 (query alias: CUDC-305) |
|---|---|
| Modality / target | Not disclosed; Not disclosed; Not disclosed |
| Highest global status | Not disclosed |
| Originator | Not disclosed |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2012-003495-39-GB | Phase 1/2 | Completed | 20 | The primary endpoint for Part 1 is the absolute bioavailability (F) of 250 mg and 500 mg Debio 0932 based on AUC∞. The primary endpoints for Part 2 are: • Mass balance recovery of total radioactivity in urine, faeces and expired air (Ae, Af, Aa, At, Fe, Ff, Fa and Ft) • Radiochromatographic characterisation of the metabolite profile of metabolites of [14C] Debio 0932 in plasma, urine and faeces |
| NCT01714037 | Phase 1 | Terminated | 82 | Occurrence of Dose Limiting Toxicities |
| NCT03675542 | Phase 1 | Unknown status | 16 | Change from baseline in Psoriasis Area and Severity Index (PASI) score |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial
Phase 1; n=15; evaluation: Positive. Reported fields: HiSCR50(week 16) = 20 % ; HiSCR50(week 16) = 60 %
A double-blind, placebo-controlled, randomised trial evaluating the efficacy and safety of a HSP90 inhibitor (RGRN-305) in hidradenitis suppurativa: a novel mechanism of action
Phase 1; n=15; evaluation: Positive. Reported fields: HiSCR50(week 16) = 1 % ; HiSCR50(week 16) = 60 %
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase
Phase 1; n=50; evaluation: Positive. Reported fields: DLT = 1600 mg, at which level three DLT occurred (febrile neutropenia, diarrhea, asthenia)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
CUDC-305 addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Not disclosed—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-09-25 | MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications | Phase 1 | Financial terms not disclosed |
| 2009-08-06 | CURIS AND DEBIOPHARM SIGN AN EXCLUSIVE LICENSE AGREEMENT COVERING THE HSP90 INHIBITOR CUDC-305 | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 4 August 2026. Counts and status fields may change as source records update.
